Financial HealthORIC ended 1Q25 with roughly $223.8M in cash, cash equivalents, and marketable securities, which should provide an operational runway into 2027.
Market PositionAs long as ORIC matches on efficacy and beats Pfizer on safety, there is a clear path for ORIC's success.
Pipeline DevelopmentORIC-944 potentially represents a best-in-class compound.